-+ 0.00%
-+ 0.00%
-+ 0.00%

Polyrizon expands U.S. patent claims for intranasal drug delivery platform

PUBT·05/04/2026 12:54:16
Listen to the news
Polyrizon expands U.S. patent claims for intranasal drug delivery platform
  • Polyrizon submitted amended claims in a U.S. patent application to broaden protection for its intranasal drug-delivery hydrogel platform beyond core mucoadhesive composition to cover drug-delivery systems and methods of use.
  • Claims target formulations using sulfated polysaccharide polymers with additional polymer components designed to form a continuous film on contact with nasal mucosa, aiming to increase drug residence time and improve bioavailability.
  • Move supports strategy to strengthen intellectual property position for intranasal delivery across local and systemic drug administration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-051171), on May 04, 2026, and is solely responsible for the information contained therein.